In this interview, Noel Bairey Merz, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top Preventive Cardiology Takeaways from 2024. Dr. Bairey Merz discusses the SELECT and SUMMIT trials, the impact of cardiac interventions on the carbon footprint, and more.

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; on behalf of the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32.

Packer M, Zile MR, Kramer CM, et al; on behalf of the SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2024;Nov 16:[ePub ahead of print].

TOPSPIN ̶̶ Treatment Optimization for Blood Pressure With Single-Pill Combinations in India. Presented by Dr. Dorairaj Prabhakaran at the American Heart Association Scientific Sessions, Chicago, IL, November 17, 2024.

Sagheer U, Al-Kindi S, Abohashem S, et al. Environmental pollution and cardiovascular disease: part 1 of 2: air pollution. JACC Adv 2023;3:100805.

Sagheer U, Al-Kindi S, Abohashem S, et al. Environmental pollution and cardiovascular disease: part 2 of 2: soil, water, and other forms of pollution. JACC Adv 2024;3:100815.

Bawa D, Ahmed A, Darden D, et al. Impact of remote cardiac monitoring on greenhouse gas emissions: Global Cardiovascular Carbon Footprint Project. JACC Adv 2023;2:100286.

Marfella R, Prattichizzo F, Sardu C, et al. Microplastics and nanoplastics in atheromas and cardiovascular Events. N Engl J Med 2024;390:900-10.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Top Takeaways from 2024: Preventive Cardiology with Noel Bairey Merz, MD, FACC